Peptides Which Bind to a Specific A-Beta-Species for the Therapy And/or Diagnosis of Alzheimer's Disease

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses new peptides that specifically bind to particular forms (species) of amyloid-beta (A-beta) associated with Alzheimer's disease. These peptides, which can be optimized derivatives of the previously known D3 peptide, show high affinity and specificity to toxic A-beta oligomers or monomers. They can be used therapeutically to prevent or neutralize toxic amyloid aggregates, or diagnostically as imaging probes for early and precise detection of Alzheimer’s pathology.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of Alzheimer's disease by neutralizing or preventing toxic amyloid-beta oligomer formation.
• Early diagnosis of Alzheimer's disease by using labeled peptides as imaging probes (e.g., with PET or MRI) that bind to early-stage A-beta aggregates in the brain.
• Monitoring progression or treatment efficacy of Alzheimer's disease by detecting changes in amyloid-beta species via imaging.
• Development of diagnostic kits for in vitro detection and quantification of amyloid-beta species in biological samples (e.g., cerebrospinal fluid, blood).
• Preventive interventions in individuals at high risk for Alzheimer's before symptom onset by reducing toxic amyloid oligomer formation.

BenefitsContent extracted from patent full text and abstract with AI.

• Offers a targeted, potentially disease-modifying therapy for Alzheimer’s disease rather than just symptom relief.
• Enables much earlier and more accurate diagnosis of Alzheimer's, possibly years before symptoms manifest.
• The peptides bind specifically and with high affinity, improving both the efficacy and safety of treatments or diagnostics compared to previous approaches.
• Cyclic or modified peptide structures enhance stability and resistance to degradation, increasing effectiveness in biological systems.
• Potential to convert toxic A-beta species into non-toxic forms, reducing neuronal damage and disease progression.
• Provides a versatile platform for therapeutic, diagnostic, and research applications in Alzheimer’s and possibly other amyloidosis-related diseases.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to peptides which bind to specific A-beta species for the therapy and/or diagnosis of Alzheimer's disease.